Silvana NovelliNov 28, 2024
Matching-Adjusted Indirect Comparison of Efficacy and Safety of #liso-cel and #Mosunetuzumab for the Treatment (Tx) of 3L+ R/R #FollicularLymphoma ... more and more excellent options for our more advanced patients. ash.confex.com/ash/2023/web...
Silvana NovelliNov 18, 2024
#openaccess review comparing the role of BsAbs versus CAR-T therapy in the treatment of RR #follicularlymphoma onlinelibrary.wiley.com/doi/full/10....

Comparative Analysis of Bispec...
Silvana NovelliNov 10, 2024
Nice review with updated info #CART vs #BsAbs in #follicularlymphoma
https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.14335
Thiago CarvalhoJan 25, 2023

My latest clinical pipeline column for @NatureMedicine is out today.
It's a look at the recent approval of mosunetuzumab, #Genentech's bispecific anti CD20/CD3 monoclonal antibody
for relapsed or refractory follicular #lymphoma.

#FollicularLymphoma #Hematology #MonoclonalAntibody #DrugDevelopment

https://www.nature.com/articles/d41591-023-00010-0

FDA approves Genentech’s bispecific antibody for lymphoma

Nature Medicine explores the latest translational and clinical research news, with data from an ongoing clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.